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Objective. The most common form of congenital adrenal hyperplasia (CAH) is 21-hydroxylase (21-OH) deficiency due to mutation
of the CYP21A2 gene. Patients with nonclassical CAH (NC-CAH) are usually asymptomatic at birth and typically present in late
childhood, adolescence, or adulthood with symptoms of excessive androgen secretion. Subfertility is relative in NC-CAH, but the
incidence of spontaneous miscarriage is higher. Here, we report a previously undiagnosed female who gave birth to a normal male
child and is planning to become pregnant again.Case Report. A 32-year-old femalewas referred to our clinic for obesity. Hermedical
history revealed that she had had three pregnancies. She was planning to become pregnant again. Her laboratory results revealed
that she had NC-CAH. Since her husband is the son of her aunt and she hadmiscarriages and intrauterin exitus in her history, their
genetic analyses were performed. Conclusion. Since most patients with NC-CAH have a severe mutation, these patients may give
birth to a child with the classical CAH (C-CAH) if their partner is also carrying a severe mutation. Females with NC-CAH who
desire pregnancy must be aware of the risk of having an infant with C-CAH.
1. Introduction
Congenital adrenal hyperplasia (CAH) is a group of auto-
somal recessive disorders that are characterized by impaired
cortisol synthesis and adrenal androgen excess, caused by
a deficiency in one of the enzymes necessary for cortisol
production [1–3]. The most common form of CAH is 21-
hydroxylase (21-OH) deficiency due to mutation of the
CYP21A2 gene, which encodes the adrenal steroid 21-OH
enzyme and is located on chromosome 6p21.3 [1, 4–9].
It can be defined as classical CAH (C-CAH), or nonclas-
sical or late-onset CAH (NC-CAH). C-CAH can be of either
the salt wasting (SW) or simple virilizing (SV) type.
NC-CAH 21-OH deficiency is much more common than
C-CAH [8], with a reported prevalence of 0.1–0.4% in the
general population [10]. It is also more frequent in certain
ethnicities such asAshkenazi Jewish,Mediterranean,Middle-
Eastern, and Indian populations [11].
Patients with NC-CAH are usually asymptomatic at birth
[7] and typically present in late childhood, adolescence, or
adulthood with symptoms of excessive androgen secretion
[12]. In adolescent and adult females, the symptoms of hyper-
androgenism include hirsutism, acne, menstrual irregularity,
androgenic alopecia, and impaired fertility [2, 6].
Subfertility is relative in NC-CAH, but the incidence of
spontaneous miscarriage is higher [2]. However, few data
regarding the fertility of NC-CAH patients are available [13].
Many females with NC-CAH conceive spontaneously,
whereas others have ovulatory infertility but respond to
glucocorticoid (GCC) or GCC plus clomiphene citrate treat-
ment. However, the risk of spontaneous miscarriage is higher
in these females compared with normal females (>25 versus
10–15%, resp.) [13–18]. Approximately 70%of individualswith
NC-CAH have a point mutation of Val281Leu at exon 7,
which prevents 20–50% of enzyme activity [19]. Previous
studies reported that 27–76% of patients with NC-CAH have
a severe mutation [13]. If their partner also carries a severe
mutation, these patients might conceive a child with C-CAH
[13].
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In this study, we report a previously undiagnosed female
who gave birth to a normal male child and is planning to
become pregnant again.
2. Case
A32-year-old femalewas referred to our clinic for obesity. She
had hypothyroidism and was using L-thyroxin replacement
therapy. Her medical history revealed that she had had three
pregnancies: one had resulted in a healthy boy, one had
resulted in ectopic pregnancy with twins and intrauterine
exitus, and the latest, which had occurred 4 months earlier,
had been terminated by miscarriage. She was planning to
become pregnant again.
A physical examination revealed that her body mass
index (BMI) was 26 kg/m2. She had no purple striae or a
buffalo hump and no hirsutism: her Ferriman-Gallwey score
was 5. Laboratory results related to obesity revealed normal
thyroid function tests, insulin resistance calculated using
the HOMA-index was 1.8, and her initial random serum
cortisol level was 17.8𝜇g/dL. Because of the high cortisol
level, 1mg dexamethasone suppression test (DMST) was
applied, which successfully suppressed her cortisol level to
0.6 𝜇g/dL. A follicular phase hormonal evaluation identified
elevated 17-OHP (12.8 ng/mL) and ACTH (56 pg/mL) levels.
The other hormonal profiles were all normal, including
follicle-stimulating hormone (FSH), luteinizing hormone
(LH), estradiol (E2), progesterone, prolactin (PRL), dehy-
droepiandrosterone sulfate (DHEA-SO4), and testosterone.
There was no pathology on pelvic ultrasonography. We next
performed an ACTH stimulation test and found 17-OHP
levels at basal, 30 and 60 minutes of 14, 21, and 26 ng/mL,
respectively, which confirmed the diagnosis of NC-CAH.
During these processes, we learned that she was a carrier
of the MTHFRC677 mutation. Before admission to our hos-
pital, karyotype analysis was performed due to the previous
miscarriage and intrauterine exitus. The results revealed a
normal constitutional karyotype of 46, XX. Her husband,
who is the son of her aunt (in other words their mothers are
sisters), also had a normal constitutional karyotype of 46, XY.
Becausewe confirmed the diagnosis ofCAHand she is related
to her husband, we also studied his laboratory tests, but no
pathology was found. Genetic analyses were then performed
on both the patient and her husband. In the genetic test
results the patient had revealed a compound heterogeneous
mutation of Q318X and P453S in the CYP21A2 gene, and
her husband revealed a 453S heterogeneous mutation in
the CYP21A2 gene. They have the same P453S mutations
in the CYP21A2 gene. Because both parents were carriers
of CYP21A2 mutations, we recommended preconception
genetic counseling to the couple. They were informed of the
risks to the fetus and newborn child, and fetal sampling was
recommended if she became pregnant. Many patients with
NC-CAH are asymptomatic and current recommendations
argue against treatment for those without symptoms [19].
Treatment with glucocorticoid therapy is typically only rec-
ommended for those individuals with symptomatic hyper-
androgenism [19]. Nonpregnant adults may be treated with
the longer-actingDMor prednisone, alone or in combination
with hydrocortisone [8]. Hydrocortisone is the preferred
treatment of pregnant women affected with CAH, because
unlike DM, it is metabolized by the placental enzyme 11-𝛽
OH steroid dehydrogenase II and does not affect the fetus [8].
We did not start treatment before pregnancy, as suggested by
the Endocrine Society guidelines [3], but, instead, planned to
begin treatment when pregnancy occurred.
3. Discussion
Unlike the situation with C-CAH, few studies have assessed
fertility in females with NC-CAH [13]. Bidet et al. ana-
lyzed 190 females with NC-CAH, 95 of whom wanted to
become pregnant [13]. They reported that 187 pregnancies
occurred in 85 females, which resulted in 141 births from
82 individuals. A total of 99 pregnancies (52.9%) occurred
before diagnosis with NC-CAH (96 spontaneous and three
with ovulation inducers), and 88 occurred after diagnosis (11
spontaneously and 77 with hydrocortisone treatment). The
miscarriage rate was 6.5% and 26.3% in the patients treated
with GCC and untreated patients, respectively. The authors
also reported that 1.5% of the infants were born with C-
CAH [13]. Birnbaum and Rose [20] observed 12 pregnancies
among 22NC-CAHpatients who desired pregnancy, whereas
Feldman et al. [16] observed that, of 20 patients wanting
pregnancy, 10 had conceived before diagnosis, and nine after
NC-CAH diagnosis and hydrocortisone treatment. Some
studies have also assessed fertility in males with NC-CAH
[19]. Although oligospermia has been reported, gonadal
functions and sperm counts are relatively normal in males
with NC-CAH, which suggests that NC-CAH might be
underdiagnosed [21, 22]. One study reported that affected
males are usually asymptomatic, and they are commonly
diagnosed after the diagnosis of a female familymember [23],
as seen in our patient’s husband.
Females with NC-CAH who desire pregnancy must be
aware of the risk of having an infant with C-CAH. The
incidence of C-CAH is 1 : 10,000–1 : 20,000, and the incidence
of carriers in the general population is 1 : 50–1 : 71 (median
1 : 60) [19]. As such, the chance of having a child with C-CAH
in a patient with C-CAH is 1 : 120 [19, 24]. Since most patients
withNC-CAHcarry a severeCYP21A2mutation in one allele,
they are at risk of having a child with C-CAH [19].Therefore,
parents with NC-CAH would be predicted to have a 1 : 240
chance of having a child with C-CAH (1/60 × 1/2) × (1 ×
1/2) [3, 19, 24]. Furthermore, because two-thirds of patients
with NC-CAH are compound heterozygotes, the predicted
incidence is ∼1 : 360 (1/60 × 1/2) × (2/3 × 1/2) [19]. One study
that investigated the pregnancy outcomes of 101 females with
NC-CAH determined that the risk of having a birth with
C-CAH was much higher (2.5%) and that at least 15% of
offspring would have NC-CAH [15]. In our case, both parents
carried heterogeneous CYP21A2 mutations: the female had
Q318X and P453S mutations, whereas her husband carried
a 453S mutation. Seventy percent of NC-CAH individuals
carry a point mutation, Val281Leu, at exon 7 [19]. P453S
and R339H are also associated with NC-CAH; also R369W
and I230T are two novel mutations associated with NC-
CAH [19]. Additionally, Q318X mutation has been reported
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in association with CAH [6]. Large deletions and a splicing
mutation that ablate enzyme activity comprise about 50%
of C-CAH alleles [3]. A nonconservative amino substitution
in exon 4 is associated with simple virilizing C-CAH [3].
Because they have the chance of giving birth to a child
with C-CAH, our parents were offered preconception genetic
counseling.
Prenatal treatment for CAH is still experimental. The
aims of treatment include the genital virilization of the
fetus, reducing the anxiety of the parents who might have
a child with ambiguous genitalia [24]. However, prenatal
treatment does not prevent the need for lifelong GCC and
mineralocorticoid (MCC) replacement therapy, and intensive
medical monitoring during infancy and later life, or the
potential life-threatening salt-wasting crises that occur when
postnatal treatment is discontinued [24]. Dexamethasone
(DM) is commonly used because it binds minimally to
cortisol-binding globulin (CBG) in the maternal blood and,
unlike hydrocortisol, it is not inactivated by placental 11-beta
hydroxysteroid dehydrogenase type II [6, 8]. Consequently,
it crosses the placenta and suppresses ACTH secretion [8]. If
karyotype or DNA analyses reveal that the fetus is male or
an unaffected female, respectively, treatment is discontinued
[8]. Because fetal genital virilization begins 6-7 weeks after
conception, treatment must be started as soon as the female
learns she is pregnant [3, 24]. However, because chorionic
villous biopsies can be obtained after 10–12 weeks for genetic
diagnosis and the procedure takes additional time, all preg-
nancies deemed to be at risk for virilizing CAH are treated,
even though only 1 in 4 is affected, and only 1 in 8 affected
fetuses is female [3, 6, 24]. Therefore, it was suggested that
DM exposure is undesirable and unethical in 7 out of 8
fetuses (males and unaffected females) [24]; this remains
controversial [24]. Because of the methodological limitations
and small sample sizes, evidence for the maternal and fetal
sequelae of prenatal DM treatment to accurately assess the
fetuses at risk for CAH is limited or is of poor quality
[3, 25]. Endocrine Society guidelines suggest that prenatal
treatment should be pursued using protocols approved by
Institutional Review Boards at all centers that are capable
of collecting outcome data from a sufficiently large number
of patients, which will allow the risks and benefits of this
treatment to be defined more precisely [3]. Therefore, we did
not start treatment before pregnancy occurred, as suggested
by Endocrine Society guidelines [3]. In the study of New and
colleagues [26], they found that the average Prader score of
the fetuses treated with DM was 1.7, which was much lower
than the average Prader score of 3.73 in those not treated.
Although their data demonstrated no significant abnormality
in the long-term medical and cognitive outcomes in the
patients treated with DM prenatally, the procedures such as
chorionic villus sampling and amniocentesis were invasive
and also all the fetuses treated unnecessarily before the sex
and the affection status of the fetus is known. In a recent study
of New et al. [27], they developed a noninvasive method for
early prenatal diagnosis of fetuses at risk for CAH and found
that cell-free fetal DNAobtained frommaternal plasma could
potentially provide the diagnosis of CAH, noninvasively,
so, only the affected female fetuses will be treated before
the 9th week of gestation. Their study seems promising. But
we decide to treat the patient when pregnancy occurs, obtain
chorionic villous sampling 10–12 weeks into the pregnancy,
and then manage the treatment appropriately.
Consent
The patient described in the case report has given informed
consent for the case report to be published.
Conflict of Interests
There is no conflict of interests in our case report.
References
[1] L. S. Levine, “Congenital adrenal hyperplasia,” Pediatrics in
Review, vol. 21, no. 5, pp. 159–171, 2000.
[2] I. N. Purwana, H. Kanasaki, A. Oride, and K. Miyazaki, “Suc-
cessful pregnancy after the treatment of primary amenorrhea
in a patient with non-classical congenital adrenal hyperplasia,”
Journal of Obstetrics and Gynaecology Research, vol. 39, no. 1, pp.
406–409, 2013.
[3] P. W. Speiser, R. Azziz, L. S. Baskin et al., “Congenital
adrenal hyperplasia due to steroid 21-hydroxylase deficiency:
an Endocrine Society clinical practice guideline,” Journal of
Clinical Endocrinology and Metabolism, vol. 95, no. 9, pp. 4133–
4160, 2010.
[4] N. Krone, V. Dhir, H. E. Ivison, and W. Arlt, “Congenital
adrenal hyperplasia and P450 oxidoreductase deficiency,” Clin-
ical Endocrinology, vol. 66, no. 2, pp. 162–172, 2007.
[5] P. C. White and P. W. Speiser, “Congenital adrenal hyperplasia
due to 21-hydroxylase deficiency,”Endocrine Reviews, vol. 21, no.
3, pp. 245–291, 2000.
[6] S. F. Witchel, “Non-classic congenital adrenal hyperplasia,”
Steroids, vol. 78, no. 8, pp. 747–750, 2013.
[7] K. Unluhizarci, M. Kula, M. Dundar et al., “The prevalence of
non-classic adrenal hyperplasia among Turkish women with
hyperandrogenism,”Gynecological Endocrinology, vol. 26, no. 2,
pp. 139–143, 2010.
[8] O. Lekarev and M. I. New, “Adrenal disease in pregnancy,” Best
Practice and Research: Clinical Endocrinology and Metabolism,
vol. 25, no. 6, pp. 959–973, 2011.
[9] S. F. Witchel, “Management of CAH during pregnancy: opti-
mizing outcomes,” Current Opinion in Endocrinology, Diabetes
and Obesity, vol. 19, no. 6, pp. 489–496, 2012.
[10] H. Pinkas, S. Fuchs, Y. Klipper-Aurbach et al., “Non-classical 21-
hydroxylase deficiency: prevalence in males with unexplained
abnormal sperm analysis,” Fertility and Sterility, vol. 93, no. 6,
pp. 1887–1891, 2010.
[11] R. C. Wilson, S. Nimkarn, M. Dumic et al., “Ethnic-specific
distribution ofmutations in 716 patientswith congenital adrenal
hyperplasia owing to 21-hydroxylase deficiency,” Molecular
Genetics and Metabolism, vol. 90, no. 4, pp. 414–421, 2007.
[12] S. F. Witchel, “Nonclassic congenital adrenal hyperplasia,”
Current Opinion in Endocrinology, Diabetes and Obesity, vol. 19,
no. 3, pp. 151–158, 2012.
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